Clinical trial
IGHID 12616 - Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy (RELAI) - The RELAI Study
NCT07895823 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started January 2027. Interventional study, Phase 4, 40 participants (estimated). Lead sponsor University of North Carolina, Chapel Hill; United States. Primary measures: Percent of preliminarily eligible participants who accept and receive field-based injection (acceptability); Median acceptability of intervention (AIM) score (acceptability) and 2 more.
How it compares
413 similar trials: same condition (HIV Infections) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- IGHID 12616 - Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy (RELAI) - The RELAI Study
- Lead sponsor
- University of North Carolina, Chapel Hill
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- September 30, 2028
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: hiv infection
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- United States
- Lead sponsor
- University of North Carolina, Chapel Hill
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| Field-based LA-CAB/RPV | Experimental | Field-based LA-CAB/RPV |
Primary endpoints
Registered primary outcome measures; 4 primary.
| Measure | Time frame |
|---|---|
| Percent of preliminarily eligible participants who accept and receive field-based injection (acceptability) | From enrollment to the end of participation at 7 months |
| Median acceptability of intervention (AIM) score (acceptability) | Month 3, Month 7 |
Show registry wordingAIM scores are calculated using the following scale: 1 = Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Completely agree. Scores are calculated from a version of the following four questions: (1) The intervention meets my approval, (2) The intervention is appealing to me, (3) I like the intervention, and (4) I welcome the intervention. Scores are summed across participant and summaries of these scores are provided, minimum score is 4 and maximum score is 20 which corresponds to perfect acceptability. | |
| Median HIV treatment burden score (acceptability) | Month 0, Month 3, Month 7 |
Show registry wordingThe Treatment burden Questionnaire (TBQ) is a self-reported questionnaire assessing the burden of treatment without restricting its scope to a single condition or treatment context. It has been adapted to include 13 items rated on a Likert scale ranging from 0 (not at all difficult) to 5 (extremely difficult) related to the burden associated with taking medicine, self-monitoring, laboratory tests, physician visits, need for organization, administrative tasks, following advice on diet and physical activity, and social impact of the treatment. Item scores can be summed into a global score, ranging from 13 to 65. Higher scores reflect higher treatment burden. | |
| Percentage of participants who receive all indicated LA-CAB/RPV injections within the allowable 14-day window (feasibility) | From enrollment to the end of participation at 7 months |
Show registry wordingAs extracted from study administration and, where appropriate, clinic records, the date of injections will be determined as falling within or outside the acceptable window period. This outcome will be calculated as the percent of all participants with an indication for receipt of LA-CAB/RPV (that is, has not been excluded from further injections identified after receipt of first injection or failure to achieve appropriate decline in HIV RNA levels or viral suppression prompting transition to alternative agent), who receive all indicated injections within the acceptable 14-day window period, as determined by the date of the prior injection. | |
Lead sponsor's other trials
University of North Carolina, Chapel Hill, most recent start first.
+1,367 more trials
Similar trials
Same condition (HIV Infections) and phase, most recent start first.
+408 more trials See the condition page